Same Receptor, Opposite Outcomes: The Contradiction Tearing Psychedelic Science Apart

Three psychedelic compounds bind to the same receptor in your brain. Two of them reduce suicidal ideation. One of them increases it. No one knows why.

This episode maps the fault lines running through psychedelic research—where the data is converging on breakthrough treatments for depression, PTSD, and addiction, while simultaneously contradicting itself on the most fundamental question: do these compounds heal, or do some of them harm?

We examine how late-stage clinical trials are delivering unprecedented results for treatment-resistant conditions, while regulatory bodies reject therapies the data supports. We trace the 71% convergence across ten unrelated scientific domains—and the 29% where the evidence tears itself apart.

At the center: the unresolved mystery of why molecules in the same family produce opposite effects on whether people want to live.

The science is succeeding. The science is also at war with itself. This is what that looks like.

psychedelic therapy research psilocybin MDMA LSD suicidal ideation treatment-resistant depression PTSD veteran mental health 5-HT2A receptor neuroplasticity FDA drug approval consciousness science brain research clinical trials

Видео Same Receptor, Opposite Outcomes: The Contradiction Tearing Psychedelic Science Apart канала Psy AI